CoChat

Global analysis of genetic circuitry and adaptive mechanisms enabling resistance to the azole antifungal drugs

Open access

The DOI matches its Crossref record; 80 of the 80 references it cites were found in a registry or an index.

Abstract

Invasive fungal infections caused by the pathogen Candida albicans have transitioned from a rare curiosity to a major cause of human mortality. This is in part due to the emergence of resistance to the limited number of antifungals available to treat fungal infections. Azoles function by targeting the biosynthesis of ergosterol, a key component of the fungal cell membrane. Loss-of-function mutations in the ergosterol biosynthetic gene ERG3 mitigate azole toxicity and enable resistance that depends upon fungal stress responses. Here, we performed a genome-wide synthetic genetic array screen in Saccharomyces cerevisiae to map ERG3 genetic interactors and uncover novel circuitry important for azole resistance. We identified nine genes that enabled erg3-mediated azole resistance in the model yeast and found that only two of these genes had a conserved impact on resistance in C. albicans. Further, we screened a C. albicans homozygous deletion mutant library and identified 13 genes for which deletion enhances azole susceptibility. Two of the genes, RGD1 and PEP8, were also important for azole resistance acquired by diverse mechanisms. We discovered that loss of function of retrograde transport protein Pep8 overwhelms the functional capacity of the stress response regulator calcineurin, thereby abrogating azole resistance. To identify the mechanism through which the GTPase activator protein Rgd1 enables azole resistance, we selected for mutations that restore resistance in strains lacking Rgd1. Whole genome sequencing uncovered parallel adaptive mechanisms involving amplification of both chromosome 7 and a large segment of chromosome 3. Overexpression of a transporter gene on the right portion of chromosome 3, NPR2, was sufficient to enable azole resistance in the absence of Rgd1. Thus, we establish a novel mechanism of adaptation to drug-induced stress, define genetic circuitry underpinning azole resistance, and illustrate divergence in resistance circuitry over evolutionary time.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pgen.1007319

Cites

80 of 80 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig 1 The ERG3 genetic interaction network in S. cerevisiae uncovers species-specific circuitry important for azole resistance. A) Genetic nodes highlighting the negative genetic interactions with an SGA score (ε) ≤ -0.25 in YPD medium. 100 genes were identified as having a genetic interaction with ScERG3, and they are coloured based on their GO Slim Process category. B) Microbroth dilution minimum inhibitory concentration (MIC) assay for S. cerevisiae ERG3 genetic interactors for which gene deletion abrogates azole resistance of the erg3 mutant. Strains were complemented with their respective wild-type allele to verify the azole sensitivity phenotype was due to the specific gene deletion. MIC assays were conducted in YPD and growth was measured by absorbance at 600 nm after 48 hours at 30°C. Optical densities were averaged for duplicate measurements. Data was quantitatively displayed with colour using Treeview (see colour bar). C) MIC assay for C. albicans erg3 homozygous deletion mutants that also harboured homozygous deletions of genes originally identified in S. cerevisiae as being important for erg3-mediated resistance. MIC assay was performed as in part B. For the bottom panel, fluconazole MIC assays were conducted in YPD medium with 1 μg/mL doxycycline to achieve transcriptional repression of the target gene in the conditional expression strains.
Fig 1 The ERG3 genetic interaction network in S. cerevisiae uncovers species-specific circuitry important for azole resistance. A) Genetic nodes highlighting the negative genetic interactions with an SGA score (ε) ≤ -0.25 in YPD medium. 100 genes were identified as having a genetic interaction with ScERG3, and they are coloured based on their GO Slim Process category. B) Microbroth dilution minimum inhibitory concentration (MIC) assay for S. cerevisiae ERG3 genetic interactors for which gene deletion abrogates azole resistance of the erg3 mutant. Strains were complemented with their respective wild-type allele to verify the azole sensitivity phenotype was due to the specific gene deletion. MIC assays were conducted in YPD and growth was measured by absorbance at 600 nm after 48 hours at 30°C. Optical densities were averaged for duplicate measurements. Data was quantitatively displayed with colour using Treeview (see colour bar). C) MIC assay for C. albicans erg3 homozygous deletion mutants that also harboured homozygous deletions of genes originally identified in S. cerevisiae as being important for erg3-mediated resistance. MIC assay was performed as in part B. For the bottom panel, fluconazole MIC assays were conducted in YPD medium with 1 μg/mL doxycycline to achieve transcriptional repression of the target gene in the conditional expression strains.CC BY · PubMed Central
Fig 2 C. albicans functional genomic screen identifies novel genetic circuitry important for azole tolerance and resistance. A) Schematic of functional genomic screen to identify genes important for fluconazole (FL) tolerance. Thirteen genes were identified and prioritized for follow-up analysis based on the robust hypersensitivity of the corresponding deletion mutants. B) The 13 genes that were identified as having important roles in fluconazole tolerance, coloured based on their GO Slim Process category. Note many genes belong to multiple categories. C) MIC assay for C. albicans erg3 homozygous deletion mutants that also harboured homozygous deletions of genes implicated in fluconazole tolerance in part B. Homozygous deletion of either RGD1 or PEP8 abrogates the erg3-mediated azole resistance phenotype. MIC assay was performed as described in Fig 1. Growth was analyzed after 24 hours (see colour bar). D) Homozygous deletion of either RGD1 or PEP8 reduces azole resistance of two resistant clinical isolates collected from an HIV patient undergoing fluconazole therapy. CaCi-2 represents an isolate collected early in treatment and CaCi-17 represents an isolate collected later in treatment. MIC assay was performed as described in part C.
Fig 2 C. albicans functional genomic screen identifies novel genetic circuitry important for azole tolerance and resistance. A) Schematic of functional genomic screen to identify genes important for fluconazole (FL) tolerance. Thirteen genes were identified and prioritized for follow-up analysis based on the robust hypersensitivity of the corresponding deletion mutants. B) The 13 genes that were identified as having important roles in fluconazole tolerance, coloured based on their GO Slim Process category. Note many genes belong to multiple categories. C) MIC assay for C. albicans erg3 homozygous deletion mutants that also harboured homozygous deletions of genes implicated in fluconazole tolerance in part B. Homozygous deletion of either RGD1 or PEP8 abrogates the erg3-mediated azole resistance phenotype. MIC assay was performed as described in Fig 1. Growth was analyzed after 24 hours (see colour bar). D) Homozygous deletion of either RGD1 or PEP8 reduces azole resistance of two resistant clinical isolates collected from an HIV patient undergoing fluconazole therapy. CaCi-2 represents an isolate collected early in treatment and CaCi-17 represents an isolate collected later in treatment. MIC assay was performed as described in part C.CC BY · PubMed Central
Fig 3 Loss of PEP8 results in abnormal vacuolar morphology and overwhelms the functional capacity of calcineurin. A) Strains of C. albicans were grown to log-phase prior to staining with membrane dye FM4-64. Images were captured using differential interference contrast (DIC) microscopy and fluorescence microscopy with a TRITC/DsRED filter set on a Zeiss Axio Observer.Z1 (Carl Zeiss) using 100x magnification. Scale bar represents 10 μm. B) Deletion of PEP8 increases fluconazole-induction of two calcineurin-dependent transcripts, UTR2 and CRH11. Transcript levels were monitored by qRT-PCR and normalized to ACT1 and GPD1. Error bars represent standard error of the mean for triplicate samples. Treatment conditions were compared using a one-way ANOVA with Bonferroni post-test. Double asterisk indicates a significant difference in transcript level relative to both wildtype with fluconazole and erg3Δ/erg3Δ strain plus fluconazole. (** P<0.01). Asterisk indicates a significant difference in transcript level relative to the wildtype and individual deletion mutants under basal conditions (* P<0.05). C) Deletion of PEP8 enhances sensitivity of C. albicans strains to the calcineurin inhibitor, FK-506, as well as the Hsp90 inhibitor geldanamycin. MIC assay was performed as described in Fig 1. Growth was measured after 24 hours.
Fig 3 Loss of PEP8 results in abnormal vacuolar morphology and overwhelms the functional capacity of calcineurin. A) Strains of C. albicans were grown to log-phase prior to staining with membrane dye FM4-64. Images were captured using differential interference contrast (DIC) microscopy and fluorescence microscopy with a TRITC/DsRED filter set on a Zeiss Axio Observer.Z1 (Carl Zeiss) using 100x magnification. Scale bar represents 10 μm. B) Deletion of PEP8 increases fluconazole-induction of two calcineurin-dependent transcripts, UTR2 and CRH11. Transcript levels were monitored by qRT-PCR and normalized to ACT1 and GPD1. Error bars represent standard error of the mean for triplicate samples. Treatment conditions were compared using a one-way ANOVA with Bonferroni post-test. Double asterisk indicates a significant difference in transcript level relative to both wildtype with fluconazole and erg3Δ/erg3Δ strain plus fluconazole. (** P<0.01). Asterisk indicates a significant difference in transcript level relative to the wildtype and individual deletion mutants under basal conditions (* P<0.05). C) Deletion of PEP8 enhances sensitivity of C. albicans strains to the calcineurin inhibitor, FK-506, as well as the Hsp90 inhibitor geldanamycin. MIC assay was performed as described in Fig 1. Growth was measured after 24 hours.CC BY · PubMed Central
Fig 4 Whole genome sequencing identifies aneuploidies that are associated with the restoration of azole resistance to a C. albicans clinical isolate lacking RGD1. A) RGD1 was deleted from a clinical isolate obtained late in treatment from a patient undergoing fluconazole therapy (CaCi-17). Resistant mutants were obtained by plating 2x108 cells on YPD plates containing a high concentration of miconazole. Spontaneous mutants were selected after 5 days at 30°C. Azole resistance of the mutants was verified by MIC assay. Cells were grown as described in Fig 1. Growth was measured after 48 hours. B) Spontaneous azole resistant mutants show fitness defect in the absence of the selective pressure but show enhanced growth in the presence of fluconazole. Strains were grown in the absence or presence of 128 μg/mL fluconazole. Growth was assessed by OD600 measurements every 15 minutes for 48 hours in a Tecan plate reader. C) Copy number variation was analyzed using the YMAP pipeline. Amplification of chromosome 7 as well as a portion of chromosome 3 occurred in all independent spontaneous resistant mutants. D) Chromosome 3 haplotype map analyzed using YMAP. The monosomic region of Chr3L was generated from different haplotypes in the four azole-resistant isolates: haplotype A (Cyan) in isolates R1 and R2, and haplotype B (magenta) in isolates R3 and R4.
Fig 4 Whole genome sequencing identifies aneuploidies that are associated with the restoration of azole resistance to a C. albicans clinical isolate lacking RGD1. A) RGD1 was deleted from a clinical isolate obtained late in treatment from a patient undergoing fluconazole therapy (CaCi-17). Resistant mutants were obtained by plating 2x108 cells on YPD plates containing a high concentration of miconazole. Spontaneous mutants were selected after 5 days at 30°C. Azole resistance of the mutants was verified by MIC assay. Cells were grown as described in Fig 1. Growth was measured after 48 hours. B) Spontaneous azole resistant mutants show fitness defect in the absence of the selective pressure but show enhanced growth in the presence of fluconazole. Strains were grown in the absence or presence of 128 μg/mL fluconazole. Growth was assessed by OD600 measurements every 15 minutes for 48 hours in a Tecan plate reader. C) Copy number variation was analyzed using the YMAP pipeline. Amplification of chromosome 7 as well as a portion of chromosome 3 occurred in all independent spontaneous resistant mutants. D) Chromosome 3 haplotype map analyzed using YMAP. The monosomic region of Chr3L was generated from different haplotypes in the four azole-resistant isolates: haplotype A (Cyan) in isolates R1 and R2, and haplotype B (magenta) in isolates R3 and R4.CC BY · PubMed Central
Fig 5 Overexpression of NPR2, a putative urea transporter located in the amplified portion of chromosome 3, in the evolved resistant isolates is sufficient to confer enhanced resistance to azoles in the absence of RGD1. A) The azole-resistant CaCi-17 rgd1Δ/rgd1Δ R1 lineage was passaged without azole and an individual colony with improved fitness in the absence of stress was selected (CaCi-17 rgd1Δ/rgd1Δ R1-A). Copy number variation was analyzed using the YMAP pipeline. Loss of amplification of chromosome 7 was observed, however, the unusual chromosome 3 aneuploidy was maintained. B) Chromosome 3 haplotype map analyzed using YMAP. For the newly evolved CaCi-17 rgd1Δ/rgd1Δ R1-A isolate, the monosomic region of Chr3L and highly amplified region of Chr3L show similar haplotype composition as the parental CaCi-17 rgd1Δ/rgd1Δ R1 strain: haplotype A (Cyan), and haplotype B (magenta). C) Azole resistance of indicated mutants was evaluated by MIC assay. Cells were grown as described in Fig 1. Growth was measured after 24 hours and normalized to the no drug control for each strain. See colour bar. D) Replacing the native promoter of one allele with the strong tetO promoter results in elevated expression of NPR2 (left panel), orf19.304 (middle panel), and orf19.344 (right panel). Addition of doxycycline reduced expression of each transcript. Transcript levels were monitored by qRT-PCR and normalized to TEF1. Error bars represent standard error of the mean for triplicate samples. Expression levels of evolved strains were compared to the parental strain using a one-way ANOVA with Bonferroni post-test. Asterisk indicates significant difference in transcript level relative to the parental strain in the absence of doxycycline (* P<0.01). E) Overexpression of NRP2 results in enhanced azole susceptibility in the CaCi-17 rgd1Δ/rgd1Δ background. Strains were grown in the absence or presence of 128 μg/mL fluconazole, 0.05 μg/mL doxycycline (DOX), or a combination of fluconazole and DOX as indicated. Growth was assessed by OD600 measurements every 15 minutes for 48 hours in a Tecan plate reader.
Fig 5 Overexpression of NPR2, a putative urea transporter located in the amplified portion of chromosome 3, in the evolved resistant isolates is sufficient to confer enhanced resistance to azoles in the absence of RGD1. A) The azole-resistant CaCi-17 rgd1Δ/rgd1Δ R1 lineage was passaged without azole and an individual colony with improved fitness in the absence of stress was selected (CaCi-17 rgd1Δ/rgd1Δ R1-A). Copy number variation was analyzed using the YMAP pipeline. Loss of amplification of chromosome 7 was observed, however, the unusual chromosome 3 aneuploidy was maintained. B) Chromosome 3 haplotype map analyzed using YMAP. For the newly evolved CaCi-17 rgd1Δ/rgd1Δ R1-A isolate, the monosomic region of Chr3L and highly amplified region of Chr3L show similar haplotype composition as the parental CaCi-17 rgd1Δ/rgd1Δ R1 strain: haplotype A (Cyan), and haplotype B (magenta). C) Azole resistance of indicated mutants was evaluated by MIC assay. Cells were grown as described in Fig 1. Growth was measured after 24 hours and normalized to the no drug control for each strain. See colour bar. D) Replacing the native promoter of one allele with the strong tetO promoter results in elevated expression of NPR2 (left panel), orf19.304 (middle panel), and orf19.344 (right panel). Addition of doxycycline reduced expression of each transcript. Transcript levels were monitored by qRT-PCR and normalized to TEF1. Error bars represent standard error of the mean for triplicate samples. Expression levels of evolved strains were compared to the parental strain using a one-way ANOVA with Bonferroni post-test. Asterisk indicates significant difference in transcript level relative to the parental strain in the absence of doxycycline (* P<0.01). E) Overexpression of NRP2 results in enhanced azole susceptibility in the CaCi-17 rgd1Δ/rgd1Δ background. Strains were grown in the absence or presence of 128 μg/mL fluconazole, 0.05 μg/mL doxycycline (DOX), or a combination of fluconazole and DOX as indicated. Growth was assessed by OD600 measurements every 15 minutes for 48 hours in a Tecan plate reader.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 80 references

Cited by

See all 34

Metadata

Authors
Mount, H. O., Revie, N. M., Todd, R. T., Anstett, K., Collins, C., Costanzo, M., Boone, C., Robbins, N., Selmecki, A., & Cowen, L. E.
Affiliations
  • University of Toronto (CA)
  • Creighton University (US)
Corresponding author
Cowen, Leah E.
Venue
PLOS Genetics
Published
2018-04-27
Volume
14
Issue
4
Pages
e1007319
ISSN
  • 1553-7390 (ISSN-L)
  • 1553-7404
OpenAlex
W2801204339
Cited by
34
References
80
Citations by year
2025: 2 · 2024: 4 · 2023: 7 · 2022: 3 · 2021: 5 · 2020: 7 · 2019: 6
FWCI
3.40
Type
journal article
Language
en
Open access
Locations
  • PLoS Genetics (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
  • Figshare (submittedVersion, cc-by)
Funders
  • National Institutes of Health (1R01AI127375-01, R01HG005853)
  • Canadian Institutes of Health Research (FDN-143264, MOP-86452, MOP-119520, FDN-154288)
  • Natural Sciences and Engineering Research Council of Canada (06261, 462167)
Topics
  • Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fungal and yeast genetics research
  • Life Sciences › Agricultural and Biological Sciences › Plant Science › Fungal Plant Pathogen Control
Keywords
azole resistance, Candida albicans, ERG3, ergosterol biosynthesis, calcineurin, retrograde transport, chromosome amplification, antifungal resistance, invasive fungal infections
MeSH terms
Whole Genome Sequencing, Antifungal Agents, Azoles, Candida albicans, Humans, Microbial Sensitivity Tests, Mutation, Mycoses, Oxidoreductases, Saccharomyces cerevisiae, GTPase-Activating Proteins, Drug Resistance, Fungal, Saccharomyces cerevisiae Proteins, Vesicular Transport Proteins, Host-Pathogen Interactions

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Global analysis of genetic circuitry and adaptive mechanisms enabling resistance to the azole antifungal drugs. https://app.cochat.ai/papers/10.1371/journal.pgen.1007319
The paper
Mount, H. O., Revie, N. M., Todd, R. T., Anstett, K., Collins, C., Costanzo, M., Boone, C., Robbins, N., Selmecki, A., & Cowen, L. E. (2018). Global analysis of genetic circuitry and adaptive mechanisms enabling resistance to the azole antifungal drugs. PLOS Genetics. https://doi.org/10.1371/journal.pgen.1007319

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.